Monthly docetaxel, combined with weekly gemcitabine, is an active and safe second-line therapy for NSCLC patients.

Monthly docetaxel, combined with weekly gemcitabine, has significant but manageable hematologic toxicity. Despite frequent dose adjustments, this doublet is very active in metastatic breast cancer, producing a high proportion of durable responses associated with favorable survival.

BACKGROUND • Programmed cell death ligand 1 (PD-L1) is expressed on many cancer and immune cells; by binding the receptor programmed cell death 1 (PD-1), a negative regulator of T-lymphocyte activation, it can block cancer immune detection 1 • Monoclonal antibodies targeting the PD-pathway and other immunecheckpoint inhibitors have shown anticancer activity in different tumor types 2 • Immune-related adverse events (AEs), including interstitial pneumonitis, colitis, and transaminitis, are known toxicities of PD-1/PD-L1 axisblocking antibodies. These toxicities are considerably higher when dual checkpoint inhibition is implemented 2-6